C-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapy
Sophia E. Schiza
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
These authors had the same contribution in this work.
Search for more papers by this authorCharalampos Mermigkis
Sleep Disorders Center, Pulmonary Department, 401 General Army Hospital, Athens, Greece
These authors had the same contribution in this work.
Search for more papers by this authorPanagou Panagiotis
Sleep Disorders Center, Pulmonary Department, 401 General Army Hospital, Athens, Greece
Search for more papers by this authorIzolde Bouloukaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleftherios Kallergis
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorNikolaos Tzanakis
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleni Tzortzaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleni Vlachaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorNikolaos M. Siafakas
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorSophia E. Schiza
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
These authors had the same contribution in this work.
Search for more papers by this authorCharalampos Mermigkis
Sleep Disorders Center, Pulmonary Department, 401 General Army Hospital, Athens, Greece
These authors had the same contribution in this work.
Search for more papers by this authorPanagou Panagiotis
Sleep Disorders Center, Pulmonary Department, 401 General Army Hospital, Athens, Greece
Search for more papers by this authorIzolde Bouloukaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleftherios Kallergis
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorNikolaos Tzanakis
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleni Tzortzaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorEleni Vlachaki
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorNikolaos M. Siafakas
Sleep Disorders Unit, Department of Thoracic Medicine, Medical School, University of Crete, Heraklion, Voutes, Greece
Search for more papers by this authorAbstract
Eur J Clin Invest 2010; 40 (11): 968–975
Background C-reactive protein (CRP) is recognized as a potential factor implicated in atherogenesis and associated cardiovascular morbidity. The aim of our study was to assess the CRP evolution during 1-year follow-up period in obstructive sleep apnoea (OSA) patients under CPAP treatment.
Methods Five hundred and twenty-eight patients with newly diagnosed moderate to severe OSA were included. CRP was assessed before CPAP initiation and at the 3rd, 6th and 12th month of the follow-up period. Patients were divided into good and poor CPAP compliance groups.
Results A significant reduction in CRP levels was observed after CPAP therapy (0·74 ± 0·62 mg dL−1 vs. 0·31 ± 0·29 mg dL−1, P < 0·001) in the whole patient group. The evolution of CRP values showed a gradual decrease at 3 months with a steep decline at 6 months, reaching a plateau after this time point. When the patients were divided into those with good and poor compliance with CPAP therapy, the above CRP evolution pattern was observed only in the former group.
Conclusion Good CPAP compliance results in a significant CRP reduction. To achieve the best positive impact on cardiovascular morbidity and mortality, a time period of at least 6 months of CPAP use is required.
References
- 1 Patil SP, Schneider H, Schwartz AR, Smith PL. Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest 2007; 132: 325–37.
- 2 Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378–84.
- 3 Shahar E, Whitney CW, Redline S, Lee ET, Newman AB, Javier Nieto F et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19–25.
- 4 Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135–43.
- 5 Somers VK, White DP, Amin R, Abraham W, Costa F, Culebras A. Sleep apnea and Cardiovascular disease: an American Heart Association/American College of Cardiology foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke council and Council of Cardiovascular Nursing. J Am Coll Cardiol 2008; 52: 686–717.
- 6 Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 2009; 64: 631–6.
- 7 Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243–60.
- 8 Minoguchi K, Yokoe T, Tanaka A, Ohta S, Hirano T, Yoshino G et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006; 28: 378–85.
- 9 Steiropoulos P, Kotsianidis I, Nena E, Tsara V, Gounari E, Hatzizisi O et al. Long term effect of continuous positive airway pressure therapy on inflammation markers of patients with obstructive sleep apnea syndrome. Sleep 2009; 32(4): 537–43.
- 10 Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–8.
- 11 Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557–65.
- 12 Heeschen C, Hamm CW, Bruemmer J, Simoons M. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric C7E3 Anti Platelet Therapy in Unstable Angina Refractory to standard treatment trial. J Am Coll Cardiol 2000; 35: 1535–42.
- 13 Cao JJ, Amold AM, Manolio TA, Polak J, Psaty B, Hirsch C et al. Association of carotid artery intima-media thickness, plaques and C-reactive protein with future cardiovascular disease and all cause mor-tality: the Cardiovascular Health Study. Circulation 2007; 116: 32–8.
- 14 Shamsuzzaman ASM, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462–4.
- 15 Kokturk O, Ciftci TU, Mollarecep E, Ciftci B. Elevated C-reactive protein levels and increased cardiovascular risk in patients with obstructive sleep apnea syndrome. Int Heart J 2005; 46: 801–9.
- 16 Punjabi NM, Beamer BA. C-reactive protein is associated with sleep disordered breathing independent of adiposity. Sleep 2007; 30: 29–34.
- 17 Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27: 1507–11.
- 18 Weaver T, Grunstein R. Adherence to continuous positive airway pressure therapy. The challenge to effective treatment. Proc Am Thorac Soc 2008; 5: 173–8.
- 19 Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G. Elevated levels of C-reactive protein and Interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129–34.
- 20 Akashiba T, Akahoshi T, Kawahara S, Majima T, Horie T. Effects of long-term nasal continuous positive airway pressure on C-reactive protein in patients with obstructive sleep apnea syndrome. Intern Med 2005; 44: 899–900.
- 21 Steiropoulos P, Tsara V, Nena F, Fitili C, Kataropoulou M, Froudarakis M et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea hypopnea syndrome. Chest 2007; 132: 843–51.
- 22 Ishida K, Kato M, Kato Y, Yanagihara K, Kinugasa Y, Kotani K et al. Appropriate use of nasal continuous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest 2009; 136: 125–9.
- 23 Torres JP, Casanova C, Celli BR. Sex, forced expiratory volume in 1s decline, body weight change and C-reactive protein in COPD pts. Eur Respir J 2009; 34: 776.
- 24 Tsara V, Serasli E, Amfilochiou A, Constantinidis T, Christaki P. Greek version of the Epworth Sleepiness Scale. Sleep Breath 2004; 8: 91–5.
- 25 A Rechtschaffen, A Kales, eds. A Manual of Standardized Terminology, Techniques, and Scoring System for Sleep Stages of Human Subjects. BIS/BRI University of California, Los Angeles; 1968.
- 26 Iber K, Ancoli-Israel S, Chesson AL, Quan SF. The AASM Manual for the Scoring of Sleep and Associated Events. Westchester, IL: American Academy of Sleep Medicine; 2007.
- 27 Steiropoulos P, Papanas N, Maltezos E, Bouros D. Is there a metabolic effect of continuous positive airway pressure in sleep apnoea? Adherence should not be underestimated. Eur Respir J 2009; 34: 1209–10.
- 28 Lévy P. From the author: Eur Respir J 2009; 34: 1210–1.
- 29 Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone mineral and soft tissue composition. Am J Clin Nutr 1990; 51: 1106–12.
